Date: March 08, 2012
Alameda, California — Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System,[i] the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.
According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes,[ii] and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott’s portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition. Specifically, the FreeStyle InsuLinx System offers:
The new FreeStyle InsuLinx blood glucose monitor includes an automated logbook, easy-to-use touch screen and personalization features.
The FreeStyle InsuLinx System is compatible with the FreeStyle InsuLinx blood glucose test strips.
"The new FreeStyle InsuLinx System represents Abbott’s latest advancement in delivering innovative products for people with diabetes who use insulin," said Heather L. Mason, senior vice president, Abbott Diabetes Care. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionally, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.
[i] FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions.
[ii] American Diabetes Association: http://www.diabetes.org/diabetes-basics/diabetes-statistics/
According to a new study published in the British Medical Journal, regularly eating white rice significantly increases the risk of Type 2 diabetes.
The authors from the Harvard School of Public Health looked for evidence of the association between eating white rice and Type 2 diabetes in previous studies and research. The new study focuses on finding a direct link between the risk and the amount of rice eaten. This study also seeks to determine if the risk of Type 2 diabetes is greater in Asian countries, whose diet consists of more white rice than westerners.
In type 2 diabetes, the body stops responding efficiently to insulin, a hormone that controls blood sugar. To compensate for the insensitivity to insulin, many diabetes drugs work by boosting insulin levels; for example, by injecting more insulin or by increasing the amount of insulin secreted from the pancreas. The new study, published in the June 9 issue of PLoS ONE, showed that a different approach could also be effective for treating diabetes — namely, blocking the breakdown of insulin, after it is secreted from the pancreas.